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Edited by Robert BaroukiAbstract Liver X receptor alpha (LXRa) is a member of the
nuclear receptor superfamily that is activated by oxysterols,
and plays a pivotal role in regulating the metabolism, transport
and uptake of cholesterol. Here, we demonstrate that LXRa also
regulates the low-density lipoprotein receptor (LDLR) gene,
which mediates the endocytic uptake of LDL cholesterol in the
liver. An LXR agonist induced the expression of LDLR in cul-
tured hepatoblastoma cells. Moreover, the LDLR promoter con-
tained an LXR response element that was recognized by LXRa/
RXRa (retinoid X receptor alpha) heterodimers in hepatoblas-
toma cells. These results suggest a novel pathway whereby
LXRa might modulate cholesterol metabolism.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The hepatic low-density lipoprotein receptor (LDLR) medi-
ates the endocytic uptake of LDL cholesterol, thereby control-
ling cholesterol levels in cells and plasma [1]. Cholesterol
regulates LDLR transcription through a negative-feedback
mechanism [2]. When cellular cholesterol levels rise, LDLR
transcription is reduced. When cellular cholesterol storage is
depleted, LDLR transcription is activated. This regulation is
controlled through speciﬁc interactions of the sterol-regulatory
element (SRE) of the LDLR promoter and the family of SRE-Abbreviations: LDLR, low-density lipoprotein; LXR, liver X receptor;
RXR, retinoid X receptor; SRE, sterol-regulatory element; SREBP,
SRE-binding protein; HMG-CoA, 3-hydroxy-3-methylglutaryl coen-
zyme A; DR4, direct repeat 4; LXRE, LXR response element; ABC,
ATP-binding cassette; CYP7A, cholesterol 7a-hydoroxylase; LPDS,
lipoprotein-deﬁcient serum; 25-HC, 25-hydroxycholesterol; PCR, po-
lymerase chain reaction; DMEM, Dulbecco’s Modiﬁed Eagle Medium;
DMSO, dimethyl sulfoxide; CMV, cytomegalovirus
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doi:10.1016/j.febslet.2006.08.010binding proteins (SREBP-1 and SREBP-2) [3]. SREBP-1 pref-
erentially activates genes involved in lipogenesis, whereas
SREBP-2 preferentially activates genes involved in the choles-
terol biosynthetic pathway [4].
Liver X receptor alpha (LXRa) is a member of the nuclear
receptor superfamily that forms a functional heterodimer with
retinoid X receptors (RXRs) [5]. LXRa/RXR heterodimers
bind to DR4-type sequence elements, known as LXR response
elements (LXREs), in their target genes. LXRa is highly ex-
pressed in the liver, intestine, macrophages and adipose tissue.
It is reported to be activated by a speciﬁc class of oxidized
derivatives of cholesterol [6,7].
Studies in the liver, activation of LXRa induces the tran-
scription of multiple genes involved in bile-acid synthesis
(CYP7A1) and sterol eﬄux (ABCG5 and ABCG8) [6,7],
whereas LXRa modulates de novo fatty-acid biosynthesis by
directly facilitating SREBP-1c gene expression [6,7]. These ef-
fects have led to the suggestion that LXRa is a sensor of the
balance between cholesterol and fatty-acid metabolism.
Both LXRa and LDLR play a pivotal role in the control of
the cholesterol levels in the liver. Thus, we aimed to evaluate
the relationship between LXRa and LDLR. In the current
study, we show that a synthetic LXR ligand regulates expres-
sion of the LDLR gene in hepatoblastoma cells. Consequently,
we demonstrate that the LDLR is a direct target for gene
expression by LXRa/RXRa heterodimers. These results sug-
gest a novel pathway whereby LXRa might become as a factor
of cholesterol homeostasis.2. Materials and methods
2.1. Materials
We obtained cholesterol, 25-hydroxycholesterol (25-HC), sodium
mevalonate and lipoprotein-deﬁcient serum (LPDS) from Sigma.
T0901317 was obtained from Cayman Chemical. The HMG-CoA
reductase inhibitor, pitavastatin, was obtained from Kowa Co.
LTD., Japan.
2.2. Plasmid constructs
The expression plasmid for human LXRa (pcDNA3-hLXRa) was
constructed as described previously [8]. To generate human LDLR
promoter reporter plasmids, LDLR promoter containing 4000 to
+57 bp (LDLR4000) was obtained by PCR with human genomic
DNA from HepG2 cells. The promoter was cloned into the
pGL4.10[luc2] vector (Promega). A deletion construct and site-directedblished by Elsevier B.V. All rights reserved.
Fig. 1. LDLR expression is regulated by the LXR agonist in Huh-7
cells. (A) Huh-7 cells were cultured in media containing pitavastatin,
LPDS or cholesterol, and treated for 24 h with vehicle or 5 lM
T0901317. LDLR mRNA levels were normalized to 18S rRNA
mRNA. All values are expressed as the mean ± S.E.M. (n = 3). The
statistical signiﬁcance of treatment versus vehicle is indicated by
*P < 0.05 or **P < 0.01. (B) Huh-7 cells were cultured in media
containing LPDS or cholesterol, and treated for 72 h with vehicle or
5 lM T0901317. Cell extracts were prepared, and aliquots (25 lg
protein per lane) were subjected to SDS–PAGE. Immunoblots were
performed with anti-LDLR antibody or anti-GAPDH antibody.
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The nucleotide sequences of these plasmids were conﬁrmed by an ABI
PRISM 310 Genetic Analyzer (Applied Biosystems).
2.3. Cell culture
Huh-7 cells were cultured in DMEMmedium containing 7.5% foetal
bovine serum (FBS). For ligand treatments, cells were cultured in
DMEM, supplemented with 5% charcoal/dextran treated FBS (Hy-
Clone) or 5% LPDS and LXR ligands. In some experiments, cells were
supplemented either with 10 lg/ml cholesterol plus 1 lg/ml 25-HC or
50 lM pitavastatin plus 50 lM mevalonate.
2.4. Quantitative real-time PCR
Real-time PCR was performed as described previously [9], using
25 ng template cDNA for each reaction. 18S rRNA was used for nor-
malizing the expression data.
2.5. Immunoblot analysis
Each cell extract (25 lg) was resolved by 7.5% SDS–PAGE, and
electroblotted to nitrocellulose membranes. Western blot analyses were
carried out using anti-human LDLR antibody (R&D System) or anti-
GAPDH antibody (Chemicon). The signals were visualized by using
SuperSignal West Dura Extended Duration chemiluminescence sub-
strate (Pierce).
2.6. Transfections and luciferase assay
The luciferase assay was performed as described previously [9].
Brieﬂy, HepG2 cells were seeded at a density of 1.6 · 104 cells/well
on 96-well plates in the presence of 10 lg/ml cholesterol and 1 lg/
ml 25-HC 14–18 h before transfection. The cells were transfected
with 50 ng LDLR reporter plasmid, 40 ng pbactin-lacZ and 20 ng
expression vector (pcDNA3 or pcDNA3-hLXRa). Twenty-four
hours after transfection, the cells were incubated with DMSO or
5 lM T0901317 in a medium containing 10% LPDS, 10 lg/ml cho-
lesterol and 1 lg/ml 25-HC. After 24 h, assays for both luciferase
and b-galactosidase were performed. We used pGL4.10[luc2] as a
negative control vector and corrected each value of the reporter gene
expression as compared to the value of the control vector. These val-
ues are expressed as fold activation compared with the control
(CMV/DMSO: control vector and DMSO treatment) in each
LDLR-reporter construct.
2.7. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from cultured HepG2-tet-oﬀ-
hLXRa cells in the absence of doxycycline for 4 days. EMSAs were
performed as described previously [8,9]. In the competition studies, a
10-fold or 50-fold molar excess of unlabeled DNAs were added to
the reaction mixture. Supershift assays were performed by using
anti-human LXRa (PPZ0412, Perseus Proteomics) or RXRa
(K8508, Perseus Proteomics) antibodies. Double-stranded DNAs
composed of the following sequences were used for the binding and
competition assays: human LDLR LXRE wild type, 5 0-GTTCCA-
GACCTGCCCTGACCTCTAG-3 0; LDLR LXRE mutant, 5 0-
GTTCCttttCTGCCCTtttCTCTAG-30; and rat CYP7A1 LXRE wild
type, 5 0-GCTTTGGTCACTCAAGTTCAAGTT-3 0 (mutated bases
are denoted by lowercase letters).
2.8. Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as described previously [9]. HepG2-tet-
oﬀ-hLXRa cells were cultured in the absence of doxycycline for 4 days.
The cells were treated with 5 lM T0901317 for 8 h. Antibodies for
LXRa (PPZ0412), RXRa (D-20; Santa Cruz), mouse IgG (Santa
Cruz) or rabbit IgG (Santa Cruz) were used. The precipitated DNAs
were analyzed by PCR using the primers 5 0-GAACGCTGTTCTG-
GAAACCTTG-3 0 and 5 0-GTGTCATGAGTCCACATCTGGTTAC-
3 0, which ﬂanked the LXRE of the LDLR promoter. The intensity
of each band was quantiﬁed by the Scion Image program (Scion Cor-
poration, USA).
2.9. Statistical analysis
All data are presented as the mean ± standard error (S.E.M.). Statis-
tical analyses were performed by unpaired Student’s t-test or Dunn–
Bonferroni’s test using Statcel version 2.0 (OMS, Japan).3. Results and discussion
3.1. LXR agonist induces LDLR expression in human
hepatoblastoma cells
LDLR expression is regulated by intracellular sterol concen-
trations [1,2]. Therefore, various cellular sterol conditions were
used to analyze the regulation of LDLR gene expression in
human hepatoblastoma cells. The mRNA expression of LDLR
gene was increased by the synthetic LXR agonist T0901317 in
sterol-depleted cells (pitavastatin or LPDS treated cells), in
which levels of nuclear SREBPs were expected to be high
(Fig. 1A). A signiﬁcant induction of LDLR expression was
also observed in LPDS medium supplemented with sterols
(cholesterol), under which conditions SREBP cleavage was
suppressed. This induction eﬀect by T0901317 was detected
in LDLR protein levels, as well as mRNA levels (Fig. 1B).
Thus, the LXR agonist induced the expression of LDLR in
hepatocytes under various cellular sterol conditions.
3.2. LXR transactivates the human LDLR promoter
To investigate the eﬀect of T0901317 on the transcription of
LDLR, we cloned this gene from human genomic DNA and
constructed a luciferase reporter plasmid containing its 5 0-ﬂank-
ing region (4000 to +57 bp) (Fig. 2A). Human hepatoblas-
Fig. 2. LXRa modulates human LDLR promoter activity via an
LXRE located between 3788 and 3773 bp. (A) Scheme representing
the luciferase reporter gene containing the LDLR promoter sequence.
Wild-type and mutated LXRE or SRE sequences (underlined) are
shown. (B, C) Reporter genes were co-transfected into HepG2 cells
with empty vector or LXRa expression vector. Transfected cells were
treated with DMSO or 5 lM T0901317. These assays were performed
in a medium containing 10 lg/mL cholesterol plus 1 lg/mL 25-HC.
Data are presented as luciferase activity normalized to b-galactosidase
activity. All values are expressed as the mean ± S.E.M. (n = 3–5). The
statistical signiﬁcance is indicated by *P < 0.05 or **P < 0.01.
Fig. 3. LXRa/RXRa heterodimers bind to the LXRE in the 3788/
3773 region of the human LDLR gene. (A) Sequence of LXRE
consensus, LDLR LXRE, and mutant LXRE. (B) A radiolabeled
DNA probe corresponding to nucleotides 3788 to 3773 of the
LDLR promoter was incubated with nuclear extracts, with or without
an excess of unlabeled probe corresponding to LDLR-LXRE (LDLR),
the mutated LXRE motif (LDLRmut) or the identiﬁed LXRE from
the ratCYP7A1 gene (CYP7A). (C) Supershift experiments were
performed with anti-LXRa (LXR), anti-RXRa (RXR) and anti-SR-A
(SRA) monoclonal antibodies. Closed and open arrowheads indicate
the speciﬁc shift bands and the supershift bands, respectively.
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sion vector along with the luciferase reporter constructs. As
shown in Fig. 2B, the LDLR promoter (LDLR4000) was
strongly enhanced by LXRa in a ligand-dependent manner.
However, LDLR expression was also regulated by SREBPs
through the SRE [3,10]. Because LXRs activate SREBP-1
expression by binding to LXRE in the SREBP-1 promoter
[6,7], it is possible that LXRa-mediated regulation of the LDLR
gene is secondary to the induction of SREBP-1. In fact, we also
detected the induction of SREBP-1 by the LXR agonist in hepa-
toblastoma cells (data not shown). To investigate whether
LXRa can directly regulate LDLR expression in a SREBP-1-
independent manner, we generated a construct containing a
point mutation in the SRE (65 to 56 bp) sequence. The
4.8-fold induction of luciferase activity mediated by LXRa on
the wild-type promoter construct (LDLR4000) was reduced to
1.8-fold induction when the SRE was mutated (LDLR-Sm).
This result demonstrated that LXRa can up-regulate the LDLR
promoter, even within the mutations of the SRE sequence.
This ﬁnding raises the possibility of the existence of an
LXRE in the promoter of the human LDLR gene. LXRa/
RXR heterodimers are known to bind to DR4. We analyzedthe sequence of the human LDLR (4000 to +57 bp) for
LXRE, as predicted by NUBIScan [11], and found a potential
binding site (3788 to 3773 bp) (Fig. 2A). In order to certify
that the eﬀects of LXRa on the human LDLR promoter are
mediated by this potential LXRE, we analyzed the reporter
gene assays using LDLR promoter constructs carrying muta-
tions and deletions (Fig. 2B). Mutation of the potential LXRE
site partly reduced the magnitude of LXRa activation (LDLR-
Lm), and simultaneous mutations of both the potential LXRE
and the SRE sites virtually abolished the eﬀect of LXR agonist
(LDLR-LSm). Furthermore, deletion of the sequence between
4000 and 3773 bp (LDLR3772) partly reduced reporter
activity as well as LDLR-Lm. When the SRE of the
LDLR3772 construct was mutated, LXRa-mediated transacti-
vation was fully abolished.
We further tested whether the potential LXRE could func-
tion as a cis-acting element. We placed three copies of this se-
quence upstream of a minimal thymidine kinase promoter and
luciferase reporter gene (TK-LXREx3). When co-transfected
with the LXRa expression vector, the TK-LXREx3 reporter
was activated (1.7-fold induction) by the LXR agonist,
whereas the empty vector TK was not responsive (Fig. 2C).
Collectively, these data are consistent with regulation of the
LDLR promoter by LXRa.
3.3. LXRa/RXRa heterodimers bind directly to the LXRE in the
LDLR promoter
Fig. 3A shows the consensus sequence for canonical LXRE
[7]. The sequence of the LDLR LXRE was very similar to the
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erodimers bind to this LXRE site in the LDLR promoter, an
EMSA was performed using this response element as a radio-
labeled probe (Fig. 3B). A labeled probe was shifted by the
incubation of nuclear extracts from human LXRa stable trans-
formants of HepG2 cells (lane 2). This labeled complex forma-
tion was disrupted by increasing amounts (10-fold and 50-fold
excess) of unlabeled self-competitor (LDLR) and rat CYP7A1
LXRE fragments (CYP7A), but not by the mutated LXRE
(LDLRmut) probes (lanes 3–8). Furthermore, no protein–
DNA complexes were observed when using the mutated
LXRE (LDLRmut) probe (lane 9). Monoclonal antibodies di-
rected against LXRa (LXR) and RXRa (RXR) gave super-
shifted bands (Fig. 3C, open arrowheads in lanes 11 and 12).
As expected, a control antibody (scavenger receptor A; SRA)
had no signiﬁcant eﬀect (lane 13). These results demonstrate
that LXRa/RXRa heterodimers bind to the LXRE site at
3788 to 3773 bp.
To investigate whether LXRa/RXRa heterodimers bind to
the LXRE in cells, we performed ChIP assays in human LXRa
stable transformants of HepG2 cells. Fragmented chromatin
from formaldehyde cross-linked cells was incubated with an
anti-LXRa (LXR) or anti-RXRa (RXR) antibody. The pre-
cipitated LXRE was detected by PCR ampliﬁcation of the
LDLR promoter fragment (3865 to 3678 bp) including
the LXRE (3788 to 3773 bp). Speciﬁc ampliﬁcation was de-
tected when antibody for LXRa or RXRa was used, but not in
the case of the control IgG (Fig. 4). These results indicate that
LXRa/RXRa heterodimers bind to the LXRE in the LDLR
promoter in hepatoblastoma cells.
LXRa is known to regulate a number of genes involved in
cholesterol homeostasis [6,7]. The current study suggests that
LXRa directly regulates the human LDLR gene. The mRNAFig. 4. ChIP assays of the LDLR promoter. ChIP assays were
performed using LXRa stable transformants of HepG2 cells. Soluble
chromatin was immunoprecipitated with pre-immune control IgG
(lanes 2, 5, 8 and 11), anti-LXRa (LXR; lanes 3 and 6) or anti-RXRa
antibody (RXR; lanes 9 and 12). Immunoprecipitates were subjected
to PCR with a primer pair speciﬁc to the LDLR promoter. As a
negative control, a second set of primers was used to amplify another
genomic region that was not expected to interact with the LXRa. PCR
was performed on total chromatin input (lanes 1, 4, 7 and 10).expression of LDLR gene was induced by the LXR agonist
T0901317 in Huh-7 cells under various cellular sterol condi-
tions (Fig. 1A). We also examined the up-regulation of LDLR
mRNA by adding T0901317 to human functional liver 4 cells
(FLC4) (data not shown). When we examined the eﬀect of
T0901317, this LXR agonist increased the expression of
LDLR protein (Fig. 1B). In particular, in comparison with
vehicle, the LXR agonist strongly induced the LDLR expres-
sion under a high cholesterol condition which suppresses
endogenous SREBPs activity. These observations support that
LXRa directly regulates the LDLR expression. Here, a func-
tional LXRE has been identiﬁed in the human LDLR pro-
moter (Fig. 2). Simultaneously, an LXR agonist inﬂuenced
the SRE in the LDLR promoter. It is noteworthy that similar
data have recently been reported for fatty acid synthase (FAS)
[12] and ileal bile acid-binding protein (I-BABP) [13], suggest-
ing that LXRE and SRE independently but additively confer
the LXR responsiveness. In fact, we also investigated that
T0901317 and pitavastatin can additively activate the LDLR
promoter (data not shown). Thus, the LDLR gene can be di-
rectly as well as indirectly up-regulated by LXRa. Finally,
we elucidated that an LXRE in the human LDLR promoter
was bound by LXRa/RXRa heterodimers in hepatoblastoma
cells (Figs. 3 and 4).
The rodent LDLR LXRE has not been identiﬁed yet. There
might be species diﬀerences between human and rodents. How-
ever, Rowe et al. [14] reported that T0901317 increased the
mRNA expression of LDLR gene in murine macrophage
J774A.1 cells. Masson et al. [15] reported the similar induction
in the liver from C57BL6 mice by T0901317. It has been sug-
gested that the eﬀects of T0901317 might regulate sensitivity to
alternations in the cholesterol content. We have shown here
that LXRa regulates human LDLR expression through the di-
rect interaction with the LDLR promoter. Further analyses are
needed to determine whether an LXRE is presented or not in
the LDLR promoter in rodents.
In conclusion, we have demonstrated for the ﬁrst time
that the SREBP-independent activation of LDLR expression
by an LXR agonist occurs via a LXRE. Therefore, we sug-
gest that LXRa aﬀects plasma cholesterol levels and that
LXRa agonists might be useful for the treatment of hyperlip-
idemia.
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